EP1014971A4 - Treatment for premenstrual dysphoric disorder - Google Patents

Treatment for premenstrual dysphoric disorder

Info

Publication number
EP1014971A4
EP1014971A4 EP98904669A EP98904669A EP1014971A4 EP 1014971 A4 EP1014971 A4 EP 1014971A4 EP 98904669 A EP98904669 A EP 98904669A EP 98904669 A EP98904669 A EP 98904669A EP 1014971 A4 EP1014971 A4 EP 1014971A4
Authority
EP
European Patent Office
Prior art keywords
treatment
dysphoric disorder
premenstrual dysphoric
premenstrual
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98904669A
Other languages
German (de)
French (fr)
Other versions
EP1014971A1 (en
Inventor
Louise R Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1014971A1 publication Critical patent/EP1014971A1/en
Publication of EP1014971A4 publication Critical patent/EP1014971A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
EP98904669A 1997-01-29 1998-01-23 Treatment for premenstrual dysphoric disorder Withdrawn EP1014971A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3617697P 1997-01-29 1997-01-29
US36176P 1997-01-29
PCT/US1998/001344 WO1998032436A1 (en) 1997-01-29 1998-01-23 Treatment for premenstrual dysphoric disorder

Publications (2)

Publication Number Publication Date
EP1014971A1 EP1014971A1 (en) 2000-07-05
EP1014971A4 true EP1014971A4 (en) 2000-07-05

Family

ID=21887075

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98904669A Withdrawn EP1014971A4 (en) 1997-01-29 1998-01-23 Treatment for premenstrual dysphoric disorder

Country Status (5)

Country Link
EP (1) EP1014971A4 (en)
JP (1) JP2001511131A (en)
AU (1) AU6248798A (en)
CA (1) CA2275777A1 (en)
WO (1) WO1998032436A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355982A (en) * 1999-11-03 2001-05-09 Lilly Co Eli Heterocyclic amino acids
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
CN101337930B (en) 2003-11-11 2010-09-08 卫材R&D管理有限公司 Urea derivative preparation process
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (en) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
JP5319306B2 (en) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8735397B2 (en) * 2010-03-29 2014-05-27 Vanderbilt University Method for treating schizophrenia and related diseases
CN102958523B (en) 2010-06-25 2014-11-19 卫材R&D管理有限公司 Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (en) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112015009004A8 (en) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd amorphous form of quinoline derivative and method of production thereof
MX368099B (en) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
HRP20221047T1 (en) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CN107427505A (en) 2015-02-25 2017-12-01 卫材R&D管理有限公司 For the method for the bitter taste for suppressing quinoline
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012485A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Treatment of disorders with duloxetine
EP0774461A1 (en) * 1995-11-16 1997-05-21 Eli Lilly And Company Excitatory amino acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (en) * 1994-08-12 2001-12-31 Lilly Co Eli Synthetic stimulating amino acids and methods of obtaining them
PT776201E (en) * 1994-08-12 2002-03-28 Lilly Co Eli COMPOSITION AND METHOD FOR TREATING ANXIETY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012485A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Treatment of disorders with duloxetine
EP0774461A1 (en) * 1995-11-16 1997-05-21 Eli Lilly And Company Excitatory amino acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9832436A1 *

Also Published As

Publication number Publication date
AU6248798A (en) 1998-08-18
JP2001511131A (en) 2001-08-07
CA2275777A1 (en) 1998-07-30
EP1014971A1 (en) 2000-07-05
WO1998032436A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
EP1014971A4 (en) Treatment for premenstrual dysphoric disorder
AU5981098A (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
SG71809A1 (en) Solution treatment apparatus
GB9700899D0 (en) Novel treatment
GB9619492D0 (en) Novel treatment
GB0226147D0 (en) Treatment for multiple sclerosis
ZA976593B (en) Novel treatment
GB9608657D0 (en) Novel treatment
GB9712869D0 (en) Hair treatment
GB9811525D0 (en) Sewage treatment
GB2331514B (en) Effluent treatment
GB9805304D0 (en) Hair treatment
GB9815497D0 (en) Treatment
GB9818524D0 (en) Inorgasmia treatment
GB9625795D0 (en) Novel treatment
GB9721692D0 (en) Novel treatment
GB9828550D0 (en) Treatment
GB9612752D0 (en) Novel treatment
GB9716742D0 (en) Treatment
GB9721693D0 (en) Novel treatment
GB9617762D0 (en) Treatment
GB9716289D0 (en) Tumour treatment
GB9710930D0 (en) Strand treatment
GB9812914D0 (en) Treatment
GB9614739D0 (en) Novel treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990726

A4 Supplementary search report drawn up and despatched

Effective date: 20000504

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 20001010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011219